Y
Yuri Rukazenkov
Researcher at AstraZeneca
Publications - 42
Citations - 9086
Yuri Rukazenkov is an academic researcher from AstraZeneca. The author has contributed to research in topics: Osimertinib & Gefitinib. The author has an hindex of 23, co-authored 38 publications receiving 5822 citations.
Papers
More filters
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Suresh S. Ramalingam,Johan Vansteenkiste,David Planchard,Byoung Chul Cho,Jhanelle E. Gray,Yuichiro Ohe,Caicun Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,R. Shah,Manuel Cobo,Ki Hyeong Lee,Parneet Cheema,Marcello Tiseo,Thomas John,Meng Chih Lin,Fumio Imamura,Takayasu Kurata,A. Todd,Rachel Hodge,M. Saggese,Yuri Rukazenkov,Jean-Charles Soria,Jean-Charles Soria,Jean-Charles Soria,Flaura Investigators +26 more
TL;DR: Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those whoreceived a comparator EGFR-TKI.
Journal ArticleDOI
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu,Masahiro Tsuboi,Jie He,Thomas John,C. Grohe,Margarita Majem,Jonathan W. Goldman,Konstantin Laktionov,Sang-We Kim,Terufumi Kato,Huu-Vinh Vu,Shun Lu,Kye-Young Lee,Charuwan Akewanlop,Chong-Jen Yu,Filippo de Marinis,Laura Bonanno,Manuel Domine,Frances A. Shepherd,Lingmin Zeng,Rachel Hodge,Ajlan Atasoy,Yuri Rukazenkov,Roy S. Herbst +23 more
TL;DR: In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among thoseWho received placebo.
Journal ArticleDOI
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Thanyanan Reungwetwattana,Kazuhiko Nakagawa,Byoung Chul Cho,Manuel Cobo,Eun Kyung Cho,Alessandro Bertolini,Sabine Bohnet,Caicun Zhou,Ki Hyeong Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andrew P. Brown,Yuri Rukazenkov,Suresh S. Ramalingam,Johan Vansteenkiste +17 more
TL;DR: Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer and these results suggest a reduced risk of CNS progression with osimert inib versus standard EGFR -TKIs.